{"protocolSection": {"identificationModule": {"nctId": "NCT00618774", "orgStudyIdInfo": {"id": "1235.16"}, "organization": {"fullName": "Boehringer Ingelheim", "class": "INDUSTRY"}, "briefTitle": "An Open-label, Long-term Study of Telmisartan Plus Amlodipine Fixed-dose Combination", "officialTitle": "An Open-label, Long-term Study of Telmisartan Plus Amlodipine Fixed-dose Combination"}, "statusModule": {"statusVerifiedDate": "2014-04", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2008-01"}, "primaryCompletionDateStruct": {"date": "2009-10", "type": "ACTUAL"}, "studyFirstSubmitDate": "2008-02-08", "studyFirstSubmitQcDate": "2008-02-19", "studyFirstPostDateStruct": {"date": "2008-02-20", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2009-12-28", "resultsFirstSubmitQcDate": "2010-02-18", "resultsFirstPostDateStruct": {"date": "2010-03-03", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2014-06-17", "lastUpdatePostDateStruct": {"date": "2014-06-27", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"oldNameTitle": "Boehringer Ingelheim, Study Chair", "oldOrganization": "Boehringer Ingelheim"}, "leadSponsor": {"name": "Boehringer Ingelheim", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "To assess the long term safety and efficacy of telmisartan plus amlodipine FDC in patients with essential hypertension who failed to control their BP with either monotherapy"}, "conditionsModule": {"conditions": ["Hypertension"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT"}, "enrollmentInfo": {"count": 259, "type": "ACTUAL"}}, "armsInterventionsModule": {"interventions": [{"type": "DRUG", "name": "telmisartan40/amlodipine5"}, {"type": "DRUG", "name": "telmisartan80/amlodipine5"}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Percentage of Participants Who Experienced Adverse Events", "description": "An adverse event is defined as any untoward medical occurrence", "timeFrame": "52 weeks"}, {"measure": "Clinically Relevant Abnormalities for Changes in Blood Pressure and Pulse Rate Due to Position Change, Seated Pulse Rate, Laboratory Parameters and ECG", "description": "Clinically relevant abnormalities for changes in blood pressure and pulse rate due to position change, seated pulse rate, laboratory parameters and ECG. New abnormal findings or worsening of baseline conditions were reported as adverse events.", "timeFrame": "First administration of study treatment to 24 hours post last dosing of study treatment."}], "secondaryOutcomes": [{"measure": "Change From Baseline in Seated Diastolic Blood Pressure at Week 8", "description": "mean reduction from pseud-baseline (after the washout) in seated diastolic blood pressure", "timeFrame": "Baseline and week 8"}, {"measure": "Change From Baseline in Seated Systolic Blood Pressure at Week 8", "description": "mean reduction from pseud-baseline (after the washout) in seated systolic blood pressure", "timeFrame": "Baseline and week 8"}, {"measure": "Seated DBP Control Rate at Trough After 8 Weeks", "description": "Percentage of patients whose DBP \\<90 mmHg after 8 weeks of treatment", "timeFrame": "week 8"}, {"measure": "Seated SBP Control Rate at Trough After 8 Weeks", "description": "Percentage of patients whose SBP \\<140 mmHg after 8 weeks of treatment", "timeFrame": "Week 8"}, {"measure": "Change From Baseline in Seated Diastolic Blood Pressure", "description": "Mean reduction from pseud-baseline (after the washout) in seated diastolic blood pressure", "timeFrame": "Baseline and week 20 / week 48"}, {"measure": "Change From Baseline in Seated Systolic Blood Pressure", "description": "mean reduction from pseud-baseline (after the washout) in seated systolic blood pressure", "timeFrame": "Baseline and week 20 / week 48"}, {"measure": "Seated DBP Control Rate at Trough After 6 and 12 Months", "description": "Percentage of patients whose DBP \\<90 mmHg.", "timeFrame": "6 months and 12 months"}, {"measure": "Seated SBP Control Rate at Trough After 6 and 12 Months", "description": "Percentage of patients whose SBP \\<140 mmHg", "timeFrame": "6 months and 12 months"}, {"measure": "Seated DBP Response Rate at Trough", "description": "Percentage of patients whose DBP \\<90 mmHg or decreased from pseudo-baseline by \\>=10 mmHg at 6 months and 12 months", "timeFrame": "6 months and 12 months"}, {"measure": "Seated SBP Response Rate at Trough", "description": "Percentage of patients whose SBP \\<140 mmHg or decreased deom pseudo-baseline by \\>=20 mmHg after 6 and 12 months", "timeFrame": "6 months and 12 months"}, {"measure": "Seated Blood Pressure Normalisation at Trough", "description": "Percentage of patients when classifying their blood pressure measurements into the following classes at 6 and 12 months:\n\nOptimal: SBP \\<120 mmHg and DBP \\<80 mmHg\n\nNormal: SBP \\>=120 mmHg or DBP \\>=80 mmHg and SBP \\<130 mmHg or DBP \\<85 mmHg\n\nHigh normal: SBP \\>=130 mmHg or DBP \\>=85 mmHg and SBP \\<140 mmHg or DBP \\<90 mmHg\n\nNo: SBP \\>=140 mmHg or DBP \\>=90 mmHg", "timeFrame": "6 months and 12 months"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n1. Patients with essential hypertension\n2. Outpatient\n\nExclusion Criteria:\n\n* Patients whose SBP \\>=180 mmHg or DBP \\>=110 mmHg at the end of treatment visit of the double-blind treatment period in the \"non-responder trials\"\n* Patients who have met any of the exclusion criteria defined in the \"non-responder trials\"", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "20 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Boehringer Ingelheim", "affiliation": "Boehringer Ingelheim", "role": "STUDY_CHAIR"}], "locations": [{"facility": "1235.16.004 Boehringer Ingelheim Investigational Site", "city": "Chofu, Tokyo", "country": "Japan", "geoPoint": {"lat": 35.64837, "lon": 139.55426}}, {"facility": "1235.16.006 Boehringer Ingelheim Investigational Site", "city": "Nishi-ku, Hiroshima, Hiroshima", "country": "Japan"}, {"facility": "1235.16.005 Boehringer Ingelheim Investigational Site", "city": "Osaka, Osaka", "country": "Japan", "geoPoint": {"lat": 34.69374, "lon": 135.50218}}, {"facility": "1235.16.007 Boehringer Ingelheim Investigational Site", "city": "Osaka, Osaka", "country": "Japan", "geoPoint": {"lat": 34.69374, "lon": 135.50218}}, {"facility": "1235.16.003 Boehringer Ingelheim Investigational Site", "city": "Shinjuku-ku, Tokyo", "country": "Japan", "geoPoint": {"lat": 35.2946, "lon": 139.57059}}, {"facility": "1235.16.001 Boehringer Ingelheim Investigational Site", "city": "Shinjyuku-ku,Tokyo", "country": "Japan"}, {"facility": "1235.16.002 Boehringer Ingelheim Investigational Site", "city": "Suita, Osaka", "country": "Japan"}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination"}, {"id": "FG001", "title": "Telmisartan 80 mg Plus Amlodipine 5 mg Fixed-dose Combination"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "211"}, {"groupId": "FG001", "numSubjects": "48"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "205"}, {"groupId": "FG001", "numSubjects": "45"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "3"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "3"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination"}, {"id": "BG001", "title": "Telmisartan 80 mg Plus Amlodipine 5 mg Fixed-dose Combination"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "211"}, {"groupId": "BG001", "value": "48"}, {"groupId": "BG002", "value": "259"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "56.8", "spread": "9"}, {"groupId": "BG001", "value": "51.1", "spread": "8"}, {"groupId": "BG002", "value": "55.8", "spread": "9"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "50"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "54"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "161"}, {"groupId": "BG001", "value": "44"}, {"groupId": "BG002", "value": "205"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Percentage of Participants Who Experienced Adverse Events", "description": "An adverse event is defined as any untoward medical occurrence", "populationDescription": "Treated set for safety, which was the analysis set including all the patients who had valid measurements after drug administration.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "52 weeks", "groups": [{"id": "OG000", "title": "Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination"}, {"id": "OG001", "title": "Telmisartan 80 mg Plus Amlodipine 5 mg Fixed-dose Combination"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "211"}, {"groupId": "OG001", "value": "48"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "77.3"}, {"groupId": "OG001", "value": "77.1"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Seated Diastolic Blood Pressure at Week 8", "description": "mean reduction from pseud-baseline (after the washout) in seated diastolic blood pressure", "populationDescription": "Full analysis set for blood pressure measurements, which was the analysis set including all the patients who had valid measurements at the reference baseline and at one or more time-points after reference baseline.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and week 8", "groups": [{"id": "OG000", "title": "Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination"}, {"id": "OG001", "title": "Telmisartan 80 mg Plus Amlodipine 5 mg Fixed-dose Combination"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "207"}, {"groupId": "OG001", "value": "48"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "20.81", "spread": "6.65"}, {"groupId": "OG001", "value": "15.75", "spread": "6.61"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Seated Systolic Blood Pressure at Week 8", "description": "mean reduction from pseud-baseline (after the washout) in seated systolic blood pressure", "populationDescription": "Full analysis set for blood pressure measurements, which was the analysis set including all the patients who had valid measurements at the reference baseline and at one or more time-points after reference baseline.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and week 8", "groups": [{"id": "OG000", "title": "Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination"}, {"id": "OG001", "title": "Telmisartan 80 mg Plus Amlodipine 5 mg Fixed-dose Combination"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "207"}, {"groupId": "OG001", "value": "48"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "33.89", "spread": "12.2"}, {"groupId": "OG001", "value": "26.44", "spread": "11.68"}]}]}]}, {"type": "SECONDARY", "title": "Seated DBP Control Rate at Trough After 8 Weeks", "description": "Percentage of patients whose DBP \\<90 mmHg after 8 weeks of treatment", "populationDescription": "FAS", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "week 8", "groups": [{"id": "OG000", "title": "Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination"}, {"id": "OG001", "title": "Telmisartan 80 mg Plus Amlodipine 5 mg Fixed-dose Combination"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "207"}, {"groupId": "OG001", "value": "48"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "91.8"}, {"groupId": "OG001", "value": "52.1"}]}]}]}, {"type": "SECONDARY", "title": "Seated SBP Control Rate at Trough After 8 Weeks", "description": "Percentage of patients whose SBP \\<140 mmHg after 8 weeks of treatment", "populationDescription": "FAS", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Week 8", "groups": [{"id": "OG000", "title": "Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination"}, {"id": "OG001", "title": "Telmisartan 80 mg Plus Amlodipine 5 mg Fixed-dose Combination"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "207"}, {"groupId": "OG001", "value": "48"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "93.2"}, {"groupId": "OG001", "value": "85.4"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Seated Diastolic Blood Pressure", "description": "Mean reduction from pseud-baseline (after the washout) in seated diastolic blood pressure", "populationDescription": "Full analysis set for blood pressure measurements, which was the analysis set including all the patients who had valid measurements at the reference baseline and at one or more time-points after reference baseline.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and week 20 / week 48", "groups": [{"id": "OG000", "title": "Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination"}, {"id": "OG001", "title": "Telmisartan 80 mg Plus Amlodipine 5 mg Fixed-dose Combination"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "207"}, {"groupId": "OG001", "value": "48"}]}], "classes": [{"title": "Week 20", "categories": [{"measurements": [{"groupId": "OG000", "value": "20.67", "spread": "7.16"}, {"groupId": "OG001", "value": "16.36", "spread": "5.93"}]}]}, {"title": "Week 48", "categories": [{"measurements": [{"groupId": "OG000", "value": "21.39", "spread": "6.6"}, {"groupId": "OG001", "value": "17.78", "spread": "7.31"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Seated Systolic Blood Pressure", "description": "mean reduction from pseud-baseline (after the washout) in seated systolic blood pressure", "populationDescription": "Full analysis set for blood pressure measurements, which was the analysis set including all the patients who had valid measurements at the reference baseline and at one or more time-points after reference baseline.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and week 20 / week 48", "groups": [{"id": "OG000", "title": "Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination"}, {"id": "OG001", "title": "Telmisartan 80 mg Plus Amlodipine 5 mg Fixed-dose Combination"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "207"}, {"groupId": "OG001", "value": "48"}]}], "classes": [{"title": "Week 20", "categories": [{"measurements": [{"groupId": "OG000", "value": "33.73", "spread": "12.55"}, {"groupId": "OG001", "value": "27.18", "spread": "11.83"}]}]}, {"title": "Week 48", "categories": [{"measurements": [{"groupId": "OG000", "value": "33.97", "spread": "11.75"}, {"groupId": "OG001", "value": "28.11", "spread": "12.78"}]}]}]}, {"type": "SECONDARY", "title": "Seated DBP Control Rate at Trough After 6 and 12 Months", "description": "Percentage of patients whose DBP \\<90 mmHg.", "populationDescription": "FAS", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "6 months and 12 months", "groups": [{"id": "OG000", "title": "Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination"}, {"id": "OG001", "title": "Telmisartan 80 mg Plus Amlodipine 5 mg Fixed-dose Combination"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "207"}, {"groupId": "OG001", "value": "48"}]}], "classes": [{"title": "Week 20", "categories": [{"measurements": [{"groupId": "OG000", "value": "90.8"}, {"groupId": "OG001", "value": "54.2"}]}]}, {"title": "Week 48", "categories": [{"measurements": [{"groupId": "OG000", "value": "92.8"}, {"groupId": "OG001", "value": "66.7"}]}]}]}, {"type": "SECONDARY", "title": "Seated SBP Control Rate at Trough After 6 and 12 Months", "description": "Percentage of patients whose SBP \\<140 mmHg", "populationDescription": "FAS", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "6 months and 12 months", "groups": [{"id": "OG000", "title": "Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination"}, {"id": "OG001", "title": "Telmisartan 80 mg Plus Amlodipine 5 mg Fixed-dose Combination"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "207"}, {"groupId": "OG001", "value": "48"}]}], "classes": [{"title": "Week 20", "categories": [{"measurements": [{"groupId": "OG000", "value": "95.7"}, {"groupId": "OG001", "value": "89.6"}]}]}, {"title": "Week 48", "categories": [{"measurements": [{"groupId": "OG000", "value": "93.2"}, {"groupId": "OG001", "value": "89.6"}]}]}]}, {"type": "SECONDARY", "title": "Seated DBP Response Rate at Trough", "description": "Percentage of patients whose DBP \\<90 mmHg or decreased from pseudo-baseline by \\>=10 mmHg at 6 months and 12 months", "populationDescription": "FAS", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "6 months and 12 months", "groups": [{"id": "OG000", "title": "Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination"}, {"id": "OG001", "title": "Telmisartan 80 mg Plus Amlodipine 5 mg Fixed-dose Combination"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "207"}, {"groupId": "OG001", "value": "48"}]}], "classes": [{"title": "Week 20", "categories": [{"measurements": [{"groupId": "OG000", "value": "97.1"}, {"groupId": "OG001", "value": "85.4"}]}]}, {"title": "Week 48", "categories": [{"measurements": [{"groupId": "OG000", "value": "98.6"}, {"groupId": "OG001", "value": "87.5"}]}]}]}, {"type": "SECONDARY", "title": "Seated SBP Response Rate at Trough", "description": "Percentage of patients whose SBP \\<140 mmHg or decreased deom pseudo-baseline by \\>=20 mmHg after 6 and 12 months", "populationDescription": "FAS", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "6 months and 12 months", "groups": [{"id": "OG000", "title": "Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination"}, {"id": "OG001", "title": "Telmisartan 80 mg Plus Amlodipine 5 mg Fixed-dose Combination"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "207"}, {"groupId": "OG001", "value": "48"}]}], "classes": [{"title": "Week 20", "categories": [{"measurements": [{"groupId": "OG000", "value": "97.6"}, {"groupId": "OG001", "value": "93.8"}]}]}, {"title": "Week 48", "categories": [{"measurements": [{"groupId": "OG000", "value": "97.6"}, {"groupId": "OG001", "value": "93.8"}]}]}]}, {"type": "SECONDARY", "title": "Seated Blood Pressure Normalisation at Trough", "description": "Percentage of patients when classifying their blood pressure measurements into the following classes at 6 and 12 months:\n\nOptimal: SBP \\<120 mmHg and DBP \\<80 mmHg\n\nNormal: SBP \\>=120 mmHg or DBP \\>=80 mmHg and SBP \\<130 mmHg or DBP \\<85 mmHg\n\nHigh normal: SBP \\>=130 mmHg or DBP \\>=85 mmHg and SBP \\<140 mmHg or DBP \\<90 mmHg\n\nNo: SBP \\>=140 mmHg or DBP \\>=90 mmHg", "populationDescription": "FAS", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "6 months and 12 months", "groups": [{"id": "OG000", "title": "Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination"}, {"id": "OG001", "title": "Telmisartan 80 mg Plus Amlodipine 5 mg Fixed-dose Combination"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "207"}, {"groupId": "OG001", "value": "48"}]}], "classes": [{"title": "Week 20: Optimal", "categories": [{"measurements": [{"groupId": "OG000", "value": "29.5"}, {"groupId": "OG001", "value": "4.2"}]}]}, {"title": "Week 20: Normal", "categories": [{"measurements": [{"groupId": "OG000", "value": "35.3"}, {"groupId": "OG001", "value": "18.8"}]}]}, {"title": "Week 20: High Normal", "categories": [{"measurements": [{"groupId": "OG000", "value": "24.2"}, {"groupId": "OG001", "value": "31.3"}]}]}, {"title": "Week 20: No", "categories": [{"measurements": [{"groupId": "OG000", "value": "11.1"}, {"groupId": "OG001", "value": "45.8"}]}]}, {"title": "Week 48: Optimal", "categories": [{"measurements": [{"groupId": "OG000", "value": "32.4"}, {"groupId": "OG001", "value": "6.3"}]}]}, {"title": "Week 48: Normal", "categories": [{"measurements": [{"groupId": "OG000", "value": "36.2"}, {"groupId": "OG001", "value": "18.8"}]}]}, {"title": "Week 48: High Normal", "categories": [{"measurements": [{"groupId": "OG000", "value": "18.4"}, {"groupId": "OG001", "value": "39.6"}]}]}, {"title": "Week 48: No", "categories": [{"measurements": [{"groupId": "OG000", "value": "13.0"}, {"groupId": "OG001", "value": "35.4"}]}]}]}, {"type": "PRIMARY", "title": "Clinically Relevant Abnormalities for Changes in Blood Pressure and Pulse Rate Due to Position Change, Seated Pulse Rate, Laboratory Parameters and ECG", "description": "Clinically relevant abnormalities for changes in blood pressure and pulse rate due to position change, seated pulse rate, laboratory parameters and ECG. New abnormal findings or worsening of baseline conditions were reported as adverse events.", "populationDescription": "Treated set", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "First administration of study treatment to 24 hours post last dosing of study treatment.", "groups": [{"id": "OG000", "title": "Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination"}, {"id": "OG001", "title": "Telmisartan 80 mg Plus Amlodipine 5 mg Fixed-dose Combination"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "211"}, {"groupId": "OG001", "value": "48"}]}], "classes": [{"title": "Blood Pressure Decreased", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Prostatic specific antigen increased", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Acute myocardial infarction", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "Arrhythmia", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Atrial fibrillation", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Extrasystoles", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Ventricular extrasystoles", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Orthostatic hypotension", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "While being treated with T20+A5, T40/A5, T80/A5, T40/A5+additional treatment, T80/A5+additional treatment and within 24 hours from the last dosing of any of them.", "eventGroups": [{"id": "EG000", "title": "Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination", "seriousNumAffected": 9, "seriousNumAtRisk": 211, "otherNumAffected": 102, "otherNumAtRisk": 211}, {"id": "EG001", "title": "Telmisartan 80 mg Plus Amlodipine 5 mg Fixed-dose Combination", "seriousNumAffected": 3, "seriousNumAtRisk": 48, "otherNumAffected": 23, "otherNumAtRisk": 48}], "seriousEvents": [{"term": "Inguinal hernia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 211}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 48}]}, {"term": "Prostatic specific antigen increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 211}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 48}]}, {"term": "Gastric cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 211}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 48}]}, {"term": "Squamous cell carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 211}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 48}]}, {"term": "Epilepsy", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 211}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 48}]}, {"term": "Calculus ureteric", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 211}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 48}]}, {"term": "Renal cyst", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 211}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 48}]}, {"term": "Renal haemorrhage", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 211}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 48}]}, {"term": "Benign prostatic hyperplasia", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 211}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 48}]}, {"term": "Pulmonary embolism", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 211}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 48}]}, {"term": "Acute myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 211}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 48}]}, {"term": "Clavicle fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 211}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 48}]}, {"term": "Cerebral infarction", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 211}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 48}]}], "otherEvents": [{"term": "Dental caries", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 12, "numAtRisk": 211}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 48}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 91, "numAtRisk": 211}, {"groupId": "EG001", "numAffected": 20, "numAtRisk": 48}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 18, "numAtRisk": 211}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 48}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract."}, "pointOfContact": {"title": "Boehringer Ingelheim Call Center", "organization": "Boehringer Ingelheim Pharmaceuticals", "email": "clintriage.rdg@boehringer-ingelheim.com", "phone": "1-800-243-0127"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01"}, "conditionBrowseModule": {"meshes": [{"id": "D000006973", "term": "Hypertension"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000017311", "term": "Amlodipine"}, {"id": "D000077333", "term": "Telmisartan"}], "ancestors": [{"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000002121", "term": "Calcium Channel Blockers"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000077264", "term": "Calcium-Regulating Hormones and Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000014665", "term": "Vasodilator Agents"}, {"id": "D000047228", "term": "Angiotensin II Type 1 Receptor Blockers"}, {"id": "D000057911", "term": "Angiotensin Receptor Antagonists"}], "browseLeaves": [{"id": "M19600", "name": "Amlodipine", "asFound": "Healthy Volunteers", "relevance": "HIGH"}, {"id": "M1770", "name": "Telmisartan", "asFound": "Fixed dose", "relevance": "HIGH"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M5381", "name": "Calcium", "relevance": "LOW"}, {"id": "M5398", "name": "Calcium, Dietary", "relevance": "LOW"}, {"id": "M5384", "name": "Calcium Channel Blockers", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M17412", "name": "Vasodilator Agents", "relevance": "LOW"}, {"id": "M4132", "name": "Angiotensin II", "relevance": "LOW"}, {"id": "M289354", "name": "Giapreza", "relevance": "LOW"}, {"id": "M4135", "name": "Angiotensinogen", "relevance": "LOW"}, {"id": "M25789", "name": "Angiotensin II Type 1 Receptor Blockers", "relevance": "LOW"}, {"id": "M28916", "name": "Angiotensin Receptor Antagonists", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "ChanBlk", "name": "Channel Blockers"}, {"abbrev": "VaDiAg", "name": "Vasodilator Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "BDCA", "name": "Bone Density Conservation Agents"}, {"abbrev": "VaCoAg", "name": "Vasoconstrictor Agents"}]}}, "hasResults": true}